Niklas Melzer

Niklas is a member of the Practice Area Competition, EU & Trade. He advises national and international clients on all aspects of German and European competition law. His practice focuses on merger control, competition law proceeding, cartel damage claims and competition compliance.

CV

Since 2024 Senior Associate, Taylor Wessing

2021 Associate, Taylor Wessing

2019 – 2020 Graduate research assistant, Taylor Wessing

职业发展

Since 2024 Senior Associate, Taylor Wessing

2021 Associate, Taylor Wessing

2019 – 2020 Graduate research assistant, Taylor Wessing

教育

2021 Second state examination, Hamburg

2019 – 2021 Legal clerkship a the Hanseatic Court of Appeal with station at the German University of Administrative Sciences Speyer and an international law firm

2019 First state examination, Hamburg

Publications

Eckpunkte einer IP-Strategie für Deutschland, in: Bundesverband der Deutschen Industrie e.V., with Stephan Manuel Nagel und Nora E. Wessendorf

会员资格和附属关系

Studienvereinigung Kartellrecht e.V.

语言

Experience

Rhinestahl Corporation on the acquisition of HYDRO Systems KG

Comprehensive legal advice to the US company Rhinestahl Corporation on all aspects of the acquisition of HYDRO Systems KG, including structuring, due diligence and contractual documentation. The acquisition led to the formation of RH Aero Systems, a company specialising in innovative aviation support concepts.

Press release

Alexander R. Roth, M.Jur. (Oxford)

Dr. Amir-Said Ghassabeh

Konstantin Körner

Lisa Seidel

Dr. Michael Brüggemann

Dr. Marco Hartmann-Rüppel, Dipl.-Volkswirt

Tim Hendricks

Niklas Melzer

Dr. Jens Wiesner, LL.M. (Chicago)

Dennis Hoppermann

Rebekka Sannmann

Dr. Philipp Weiten, LL.M.

Timo Stellpflug

Alessa Steigertahl

Dieter Lang, LL.M.Eur.

Kris Breudel, LL.M. (Aberdeen)

Dr. Daniel Graske

Niels Heim

Jonas Warnken

Formycon

Under the leadership of the Frankfurt-based Taylor-Wessing partners Lars-Gerrit Lüßmann and Michael Sinhart, Formycon AG and ATHOS KG are merging their development activities in the field of so-called biosimilars, the follow-up products of biological medicines (biologics), in a long-term strategic partnership. The centrepiece of this agreement is Formycon AG’s participation in the rights of two biosimilars. The volume of the legally complex transaction (aggregate counter-performance) adds up to approximately 650 million euros.

Press release

Dr. Sebastian Beyer, LL.M. (Auckland)

Tobias Kraut

Felipe Villena

Clemens Niedner

Niklas Melzer

Prof. Dr. Michael Johannes Pils

Marcus Hartmann

Dr. Andrea Sautter

Dr. Angela Knierim